Business
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that four abstracts featuring data from independent studies conducted by ProSense® users were accepted and presented at the Radiological Society of North America's ("RSNA") Annual Meeting, which took place from November 30 to December 4, 2025 in Chicago, Illinois.
About this update from Icecure Medical Ltd.
[{"type":"text","content":"Abstracts presented include 3 studies involving 263 patients, adding to a growing body of evidence across diverse patient populations supporting broader adoption of ProSense®","length":174,"tagName":"p","attribs":{}},{"type":"text","content":"CAESAREA, Israel, Dec. 10, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that four abstracts featuring data from independent studies conducted by ProSense® users were accepted and presented at the Radiological Society of North America's ("RSNA") Annual Meeting, which took place from November 30 to December 4, 2025 in Chicago, Illinois.","length":601,"tagName":"p"},{"type":"image","alt":"IceCure Medical Logo","displaySize":"","headline":null,"caption":"IceCure Medical Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/2XUcwzAVdZCf5Oz2LQaIEw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b733b9648e0c5c7b36e9d5bf48d042cc","width":400,"height":200}}},{"type":"text","content":"The RSNA's Annual Meeting, the world's largest radiology conference with around 50,000 attendees from 160 countries, is a prestigious global platform for presenting clinical data. The acceptance of four abstracts this year, each showcasing results achieved with IceCure's technology, represents another significant international recognition of the effectiveness and growing adoption of ProSense® by the medical community for the treatment of breast cancer.","length":473,"tagName":"p"},{"type":"text","content":""The broad range of independent studies conducted, peer reviewed, published and presented by ProSense® users supports the widescale adoption of our cryoablation system and is highly encouraging for women who seek a non-surgical option," said Eyal Shamir, IceCure's Chief Executive Officer. "At RSNA 2025, radiologists from across the U.S. and the globe gathered to learn about the latest technologies that can...